Zadaxin

Zadaxin

thymalfasin

Manufacturer:

SciClone

Distributor:

DKSH
Concise Prescribing Info
Contents
Thymosin α-1 (thymalfasin)
Indications/Uses
As monotherapy or combination therapy w/ interferon for treatment of chronic hepatitis B. Combination therapy w/ interferon for treatment of chronic hepatitis C. Adjuvant for flu vaccination in immunocompromised patients. Adjuvant therapy for chemotherapy-induced immune depression, immune insufficiency & immune suppression in non-small cell cancer lung carcinoma (NSCLC), malignant melanoma, hepatocellular carcinoma (HCC), breast cancer, non-Hodgkin's lymphoma (CHOP program), colorectal cancer, head & neck cancer, leukemia's pancreatic carcinoma & renal cell carcinoma.
Dosage/Direction for Use
SC Chronic hepatitis B 1.6 mg twice a wk for 6-12 mth. Patients <40 kg 40 mcg/kg. Chronic hepatitis C 1.6 mg twice a wk for 12 mth. Patients <40 kg 40 mcg/kg. Vaccine adjuvant 1.6 mg SC twice a wk w/ doses separated by 3 or 4 days & 1st dose given coincident w/ the vaccine. Single-dose regimen: 4 wk. Multidose regimen: Twice a wk for 3 wk (a total of 5-6 doses) after the last vaccination. Cancer 1.6 mg using various schedules for 6 mth or given between chemotherapy cycles.
Contraindications
Hypersensitivity. Immunocompromised patients.
Special Precautions
Do not inj IV. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Local discomfort at inj site. Rarely, erythema, transient muscle atrophy, polyarthralgia combined w/ hand edema, rash.
Drug Interactions
ATC Classification
L03AX - Other immunostimulants ; Used as immunostimulants.
Presentation/Packing
Form
Zadaxin inj 1.6 mg
Packing/Price
1 mL x 2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in